Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$31.11
-5.8%
$31.00
$24.10
$62.53
$3.09B0.25818,867 shs923,475 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$17.91
-2.0%
$15.78
$12.72
$34.47
$3.13B0.631.22 million shs1.03 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$46.18
-0.4%
$40.67
$19.45
$53.27
$3.02B2.18617,754 shs501,454 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+3.51%+3.22%+7.03%+8.55%-38.68%
Immunovant, Inc. stock logo
IMVT
Immunovant
+2.64%+4.46%+19.40%+20.66%-39.03%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+1.85%+2.52%0.00%+78.48%-1.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.3543 of 5 stars
3.40.00.03.71.92.50.0
Immunovant, Inc. stock logo
IMVT
Immunovant
1.5136 of 5 stars
3.40.00.00.02.81.70.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.9612 of 5 stars
4.51.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00
N/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.80
Moderate Buy$69.50123.40% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.82
Moderate Buy$36.30102.68% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.05
Buy$59.1128.00% Upside

Current Analyst Ratings Breakdown

Latest CNVY, CRNX, IMVT, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/10/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$36.00
7/10/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$18.00
7/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $60.00
6/25/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$337.60M2.28$0.46 per share22.90$7.35 per share1.43
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,800.80N/AN/A$14.29 per share2.18
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M63.89N/AN/A$12.90 per share3.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
-$9.98M-$0.10N/A25.63N/A-1.90%0.08%0.05%N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)

Latest CNVY, CRNX, IMVT, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.13N/AN/AN/A$0.52 millionN/A
8/6/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.84N/AN/AN/A$17.37 millionN/A
8/5/2025Q1 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.69N/AN/AN/AN/AN/A
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/A$0.16 million
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.50
2.20
1.60
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
11.16
11.16
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49

Institutional Ownership

CompanyInstitutional Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
85.28%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
6.20%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.80%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
3,80073.19 million68.66 millionNot Optionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million89.32 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120171.07 million167.99 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable

Recent News About These Companies

Kymera Therapeutics Inc (KYMR) - Investing.com
Brookline Capital Management Comments on KYMR Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Convey Health Solutions stock logo

Convey Health Solutions NYSE:CNVY

Convey Health Solutions Holdings, Inc. provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company also offers health plan management, data analytics, supplemental benefit, advisory, and software services. The Advisory Services segment offers sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. It serves government sponsored, medicare advantage, medicare, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Health Solutions Holdings, Inc. is a former subsidiary of TPG Cannes Aggregation, L.P.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$31.11 -1.91 (-5.78%)
Closing price 04:00 PM Eastern
Extended Trading
$31.46 +0.34 (+1.11%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$17.91 -0.37 (-2.02%)
Closing price 04:00 PM Eastern
Extended Trading
$18.03 +0.12 (+0.67%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$46.18 -0.17 (-0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$46.87 +0.69 (+1.50%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.